Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson’s disease. Based in Toronto, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million.

Property Value
dbo:abstract
  • Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson’s disease. Based in Toronto, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million. (en)
dbo:foundingYear
  • 1984-01-01 (xsd:date)
dbo:industry
dbo:location
dbo:parentCompany
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 20421670 (xsd:integer)
dbo:wikiPageRevisionID
  • 737417499 (xsd:integer)
dbp:logo
  • File:Cynapsus Therapeutics logo.jpg
dbp:tradedAs
  • ,
dct:subject
rdf:type
rdfs:comment
  • Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson’s disease. Based in Toronto, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million. (en)
rdfs:label
  • Cynapsus Therapeutics (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Cynapsus Therapeutics Inc. (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of